Dan Roden
Faculty Member
Last active: 3/24/2020


Roden DM, McLeod HL, Relling MV, Williams MS, Mensah GA, Peterson JF, Van Driest SL
Lancet. 2019 394 (10197): 521-532

PMID: 31395440 · PMCID: PMC6707519 · DOI:10.1016/S0140-6736(19)31276-0

Genomic medicine, which uses DNA variation to individualise and improve human health, is the subject of this Series of papers. The idea that genetic variation can be used to individualise drug therapy-the topic addressed here-is often viewed as within reach for genomic medicine. We have reviewed general mechanisms underlying variability in drug action, the role of genetic variation in mediating beneficial and adverse effects through variable drug concentrations (pharmacokinetics) and drug actions (pharmacodynamics), available data from clinical trials, and ongoing efforts to implement pharmacogenetics in clinical practice.

Copyright © 2019 Elsevier Ltd. All rights reserved.

MeSH Terms (5)

Clinical Trials as Topic Drug-Related Side Effects and Adverse Reactions Humans Pharmacogenetics Pharmacogenomic Variants

Connections (1)

This publication is referenced by other Labnodes entities: